Skip to content
    Real-World Studies

    Real-World Effectiveness and Prognostic Drivers of Tafasitamab in Relapsed or Refractory DLBCL

    Saverno et alEJHaem

    Tafasitamab, a CD19-directed immunotherapy approved in combination with lenalidomide for transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), was evaluated in a retrospective, physician-abstracted US chart review to assess treatment patterns and effectiveness in routine care. The cohort included 181 adult patients (64% White) treated across US centers, with 83% of participating clinicians practicing in community oncology settings. Across a median follow-up of 14.7 months since tafasitamab initiation, 72% of patients received the agent in the second-line setting.
    The real-world overall response rate was 73.5% (95% CI, 67.0%–79.9%). The median real-world progression-free survival was 11.3 months (95% CI, 9.8–13.6 months), and the median real-world overall survival reached 24.8 months (95% CI, 17.8 months–not estimable).
    Multivariable Cox proportional hazards regression identified clinical features significantly correlated with adverse survival outcomes. Factors independently predicting an increased risk of disease progression included later-line tafasitamab administration (third- to fifth-line vs. second-line), bulky disease, Ann Arbor stage III–IV disease (vs. stage I–II), and higher baseline Charlson Comorbidity Index scores. Furthermore, increased mortality risk was independently associated with older age, later-line administration (third- to fifth-line vs. second-line), bulky disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher. These findings demonstrate the clinical effectiveness of tafasitamab in predominantly community-based US practice, with the greatest benefit observed in earlier lines of therapy.

    Key Takeaways

    • In routine US clinical practice, tafasitamab achieved a real-world overall response rate of 73.5% (95% CI, 67.0%–79.9%), with a median progression-free survival of 11.3 months (95% CI, 9.8–13.6) and a median overall survival of 24.8 months (95% CI, 17.8–NE).
    • Multivariable Cox proportional hazards analysis demonstrated that initiation in third- to fifth-line therapy (vs. second-line) and bulky disease were independent risk factors associated with both increased disease progression and higher overall mortality.